Emerging immunotherapy technologies are transforming treatment for gastrointestinal cancers, with companies developing novel combination strategies to activate immune responses in historically resistant tumors. The global cancer immunotherapy market is projected to reach $443.17 billion by 2030.

Genmab has successfully acquired 94.2% of Merus N.V.'s outstanding shares at $97 per share, adding petosemtamab to its portfolio and positioning itself for potential billion-dollar revenue by 2029.

Genmab A/S has completed a $2.5 billion notes offering, including $1.5 billion in senior secured notes and $1.0 billion in senior unsecured notes, to fund its acquisition of Merus N.V. and related expenses.

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for three companies involved in merger and acquisition transactions.

Merus reported positive interim clinical data for petosemtamab, a bispecific antibody targeting EGFR and LGR5, showing 100% response rate in first-line left-sided metastatic colorectal cancer and 62% response rate in second-line treatment, with a manageable safety profile.